Table V.
Response data.
| Response | Older HL Treatment Arms | |||
|---|---|---|---|---|
| ABVD | Stanford V | |||
| N | % | N | % | |
| Complete response | 6 | 26 | 4 | 19 |
| Clinical complete response | 9 | 39 | 9 | 43 |
| Partial response | 2 | 9 | - | - |
| No change/stable | 4 | 17 | 2 | 10 |
| Progression | - | - | 2 | 10 |
| Unevaluable | 2 | 9 | 3 | 14 |
| Missing | - | - | 1 | 4 |
| Response | HL Age Group | |||
| < 60 years | ≥ 60 years | |||
| N | % | N | % | |
| Complete response | 122 | 16 | 10 | 23 |
| Clinical complete response | 411 | 55 | 18 | 41 |
| Partial response | 58 | 8 | 2 | 4 |
| No change/stable | 69 | 9 | 6 | 14 |
| Progression | 7 | 1 | 2 | 5 |
| Unevaluable | 61 | 8 | 5 | 11 |
| Missing | 22 | 3 | 1 | 2 |
Abbreviations: HL, Hodgkin lymphoma; N, number; ABVD, adriamycin, bleomycin, vinblastine, dacarbazine.